191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors

MLA

A. Jimeno, et al. “191P Preliminary Biomarker and Safety Results of SQZ-PBMC-HPV at RP2D in Monotherapy and Combination with Checkpoint Inhibitors in HLA A*02+ Patients with Recurrent, Locally Advanced, or Metastatic HPV16+ Solid Tumors.” Immuno-Oncology and Technology, vol. 16, Dec. 2022, p. 100303. EBSCOhost, https://doi.org/10.1016/j.iotech.2022.100303.

APA

A. Jimeno, N.R. Miselis, J.C. Park, J. Jennings, N. Dhani, U. Holtick, W.T. Iams, K. Rodabaugh, N. Nair, M. Kornacker, S.M. Loughhead, H. Bernstein, R. Zwirtes, R.R. Ji, M. Warren, & A. Sharei. (2022). 191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors. Immuno-Oncology and Technology, 16, 100303. https://doi.org/10.1016/j.iotech.2022.100303

Chicago

A. Jimeno, N.R. Miselis, J.C. Park, J. Jennings, N. Dhani, U. Holtick, W.T. Iams, et al. 2022. “191P Preliminary Biomarker and Safety Results of SQZ-PBMC-HPV at RP2D in Monotherapy and Combination with Checkpoint Inhibitors in HLA A*02+ Patients with Recurrent, Locally Advanced, or Metastatic HPV16+ Solid Tumors.” Immuno-Oncology and Technology 16 (December): 100303. doi:10.1016/j.iotech.2022.100303.